CDC latest Guidance on New Hexavalent Vaccine for Infants

Guidance for Use-

1. The vaccine is indicated for use in infants at ages 2, 4, and 6 months and is licensed for use in children aged 6 weeks through 4 years. It counts as the first three doses of the DTaP vaccine;
2. It should not be given as the fourth or fifth dose.
3. In addition, the fourth dose of IPV must be given separately to protect against polio, and a booster dose of Hib conjugate vaccine must also be given.
4. When needed, DTaP-IPV-Hib-HepB can be administered in a catch-up schedule for children under age 5 years. Of note, the observed rate of fever was higher with this combination vaccine than with the DTaP-IPV/Hib pentavalent vaccine (roughly 47% vs. 34%).

Before the routine use of Hib vaccines, incidence of H. influenzae meningitis among American Indian/Alaska Native (AI/AN) infants peaked at a younger age (4–6 months) than it did among other U.S. infant populations (6–7 months). Vaccination with a primary series of a Hib vaccine that contains PRP-OMP is preferred for AI/AN infants to provide early protection because these vaccines can provide a protective antibody response after the first dose 

For further reference log on to :

MMWR article